Shang‐Yi Huang

机构：National Taiwan University Hospital · ORCID：0000-0001-5688-3410

发表论文 155 篇 · 总被引 5332 次 · h-index 41

代表论文

• Isatuximab-pomalidomide-dexamethasone <i>versus</i> pomalidomide-dexamethasone in patients with relapsed and refractory multiple myeloma: final overall survival analysis (2024 · Haematologica · 被引 11)
• A systematic review on the epidemiology and treatment options of multiple Myeloma in Asia (2024 · Heliyon · 被引 9)
• Transglutaminase 2–mediated glutamine deamidation enhances p21 stability during senescence (2025 · Proceedings of the National Academy of Sciences · 被引 8)
• Carfilzomib, dexamethasone, and daratumumab in Asian patients with relapsed or refractory multiple myeloma: post hoc subgroup analysis of the phase 3 CANDOR trial (2021 · International Journal of Hematology · 被引 8)
• Isatuximab-Pomalidomide-Dexamethasone Versus Pomalidomide-Dexamethasone in East Asian Patients With Relapsed/Refractory Multiple Myeloma: ICARIA-MM Subgroup Analysis (2022 · Clinical Lymphoma Myeloma & Leukemia · 被引 7)
• PB2130: MAGNETISMM-6: A PHASE 3 STUDY OF ELRANATAMAB + DARATUMUMAB + LENALIDOMIDE VS DARATUMUMAB + LENALIDOMIDE + DEXAMETHASONE IN TRANSPLANT INELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA (2023 · HemaSphere · 被引 6)